Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion
Source: SeekingAlpha
2026-02-26 11:10:49 ET
Overview
I’ve covered Fulcrum ( FULC ) a couple of times in the past. It has a new look today. In 2023, Fulcrum was evaluating losmapimod in a registrational-enabling study in Facioscapulohumeral Muscular Dystrophy. I was not very confident ahead of the readout given the drug’s past performance and recommended a " Hold ." In 2024, Fulcrum announced that losmapimod flunked the test and later suspended its development altogether....
Read the full article on Seeking Alpha
For further details see:
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion
Fulcrum Therapeutics Inc.
NASDAQ: FULC
FULC Trading
-4.37% G/L:
$7.765 Last:
578,156 Volume:
$7.82 Open:
FULC Latest News
February 24, 2026 07:01:00 am
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
FULC Stock Data
$674,114,174
28,956,568
0.71%
49
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
